Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878075 | 0.92 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL4882264 | 0.83 | MAPT (0.39) | MAPTALDH1A1L3MBTL1MAPK1ATM | |
| SCHEMBL4881627 | 0.76 | MAPT (0.35) | MAPTALDH1A1MAPK1ATMKDM4E | |
| SCHEMBL4881646 | 0.74 | DGAT1 (0.33) | ALDH1A1L3MBTL1DGAT1 | |
| SCHEMBL4879118 | 0.73 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL4880920 | 0.71 | SCN9A (0.38) | MAPTALDH1A1L3MBTL1MAPK1ATM | |
| SCHEMBL4878069 | 0.69 | SMN1; SMN2 (0.35) | MAPTALDH1A1MAPK1KDM4EKMT2A | |
| SCHEMBL4881051 | 0.68 | RAB9A (0.38) | MAPTALDH1A1L3MBTL1MAPK1KDM4E | |
| SCHEMBL4878149 | 0.68 | LMNA (0.41) | MAPTALDH1A1NPSR1 | |
| SCHEMBL3614731 | 0.68 | RAB9A (0.39) | MAPTALDH1A1L3MBTL1MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| EP-1819701-A1 | CYCLIC IMINOCARBAMATES AND USE THEREOF | Bayer HealthCare AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006058630-A1 | CYCLIC IMINOCARBAMATES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | F2, UQCRB, F12 | MAPT 4803/4885ALDH1A1 348/4885L3MBTL1 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.